Hong Kong's Touyun Biotech profit surges on fair value gains

Touyun Biotech

28/08/2026 13:19

Overview
Hong Kong biotech firm's interim revenue declined slightly yr/yr for six months ended June 2026
Profit for the period surged, driven by a sharp rise in other income and gains
Earnings per share attributable to owners rose to HK7.05 cents from HK0.40 cents

Outlook
Company did not provide specific financial guidance or outlook for future periods

Result Drivers
INVESTMENT FAIR-VALUE GAINS – Profit from continuing operations rose, mainly due to higher FVTPL gains, including HK$194.2 mln on listed investments
LOW-MARGIN PRICING – Gross margin fell to 25.8% from 37.0%, primarily due to high-volume, low-margin pricing and higher RMB-denominated raw-material and labour costs

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
HK$35.40 mln
 

Reuters Recommended Reads
Aug 28 - Hong Kong's Frontage Holdings H1 profit more than doubles on Teddy Lab acquisition
Aug 26 - Hong Kong's SSY Group H1 profit rises on infusion solutions growth
Aug 26 - Uni-Bio Science H1 revenue falls 12% on pricing changes

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)